Tags

Type your tag names separated by a space and hit enter

Dosing the antipsychotic medication olanzapine.
J Clin Psychiatry. 1997; 58 Suppl 10:45-9.JC

Abstract

Olanzapine is a new antipsychotic agent with serotonin/dopamine antagonism action. Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol. Superior efficacy for negative and depressive symptoms was shown in comparison to haloperidol. Olanzapine has a favorable acute and tardive extrapyramidal symptom profile relative to haloperidol and caused substantially less elevation of serum prolactin. Dose-related weight gain and asymptomatic mild transaminase elevations occurred in olanzapine-treated patients.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga 30322, USA.

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis

Language

eng

PubMed ID

9265916

Citation

Nemeroff, C B.. "Dosing the Antipsychotic Medication Olanzapine." The Journal of Clinical Psychiatry, vol. 58 Suppl 10, 1997, pp. 45-9.
Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:45-9.
Nemeroff, C. B. (1997). Dosing the antipsychotic medication olanzapine. The Journal of Clinical Psychiatry, 58 Suppl 10, 45-9.
Nemeroff CB. Dosing the Antipsychotic Medication Olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:45-9. PubMed PMID: 9265916.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dosing the antipsychotic medication olanzapine. A1 - Nemeroff,C B, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 45 EP - 9 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 58 Suppl 10 N2 - Olanzapine is a new antipsychotic agent with serotonin/dopamine antagonism action. Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol. Superior efficacy for negative and depressive symptoms was shown in comparison to haloperidol. Olanzapine has a favorable acute and tardive extrapyramidal symptom profile relative to haloperidol and caused substantially less elevation of serum prolactin. Dose-related weight gain and asymptomatic mild transaminase elevations occurred in olanzapine-treated patients. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/9265916/Dosing_the_antipsychotic_medication_olanzapine_ L2 - http://www.psychiatrist.com/jcp/article/pages/1997/v58s10/v58s1008.aspx DB - PRIME DP - Unbound Medicine ER -